MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for mnkd
-0.008 (-1.65%)
Real-time:   12:05PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.50 - 0.51
52 week 0.44 - 3.79
Open 0.50
Vol / Avg. 558,479.00/3.62M
Mkt cap 232.39M
P/E     -
Div/yield     -
EPS -0.86
Shares 478.05M
Beta 2.27
Inst. own 19%
Nov 7, 2016
Q3 2016 MannKind Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 12, 2016
MannKind Corp at Rodman & Renshaw Global Investment Conference - Webcast
Aug 8, 2016
Q2 2016 MannKind Corp Earnings Call
Aug 8, 2016
Q2 2016 MannKind Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -103.28% -141.48%
Return on average equity - -
Employees 192 -
CDP Score - -


25134 Rye Canyon Loop Ste 300
VALENCIA, CA 91355-5031
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Officers and directors

Kent Kresa Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Matthew Jonathan Pfeffer Chief Executive Officer, Chief Financial Officer, Director
Age: 58
Bio & Compensation  - Reuters
Rose Alinaya Senior Vice President, Principal Accounting Officer
Age: 54
Bio & Compensation  - Reuters
Linda Adreveno Senior Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Joseph Kocinsky Chief Technology Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Michael E. Castagna Pharm.D. Corporate Vice President, Chief Commercial Officer
Age: 39
Bio & Compensation  - Reuters
Raymond W. Urbanski M.D., Ph.D. Corporate Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
James S. Shannon M.D. Director
Age: 59
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 72
Bio & Compensation  - Reuters